NLS Saniona

Saniona announced July 26th that the U.S. Food and Drug Administration had granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation, the company states. Saniona is preparing to initiate two Phase 2b studies of Tesomet in […]

Saniona has announced results from its 24-week double blind, randomized, placebo-controlled Phase 2 trial evaluating the safety and efficacy of Tesomet in patients with hypothalamic obesity (HO). The study results showed that Tesomet was safe and well tolerated. Furthermore, efficacy data was also reported, with statistically significant improvements in body weight, waist circumference, and glycemic […]

Boehringer Ingelheim and Saniona, a Nordic biotech company in the field of ion channel drug discovery, today announced that they have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia. Saniona may receive up to €90 million in milestone payments including an upfront payment of […]

Saniona, a biotech company in the field of ion channels, has announced that the University of Pennsylvania Treatment Research Center (TRC) has initiated recruitment of patients in a Phase 2a study for their compound, NS2359, for treatment of cocaine addiction. Today there are no approved drugs to treat cocaine addiction. The trial comprises a total of up […]

The Danish biotechnology company has announced a drug developement collaboration with the global pharma giant. Saniona, previously known under the name Aniona, focuses on small molecule drug discovery within the ion channel field. The collaboration with Pfizer involves research on pharmaceuticals to treat neurological diseases and makes use of Saniona’s expertise within the ion channel field, […]